Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A

TY - JOUR

T1 - Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A

AU - Smith, Mark P.

AU - Rupon, Jeremy

AU - Wali, Yasser

AU - Rimawi, Hala

AU - Korth-Bradley, Joan

AU - Smith, Lynne

AU - Rendo, Pablo

N1 - Funding Information: This study was sponsored by Pfizer Inc. Medical writing and editorial support were provided by Michael D. Morren, RPh, MBA, of Peloton Advantage, LLC, an OPEN Health company, and funded by Pfizer Inc. No author received an honorarium related to the development of this manuscript. Mark P. Smith, Hala Rimawi, and Yasser Wali have no conflicts to disclose. Jeremy Rupon, Joan Korth‐Bradley, and Lynne Smith are employees of Pfizer Inc and own stock in the company. Pablo Rendo was an employee of Pfizer Inc at the time of this research and may own stock in the company. Funding Information: The authors thank the participating parents and caregivers, without whom this study could not have been done. Michael Morren, RPh, MBA, of Peloton Advantage, an OPEN Health company, provided medical writing and editorial support, which were funded by Pfizer Inc.

PY - 2020/9/1

Y1 - 2020/9/1

UR - http://www.scopus.com/inward/record.url?scp=85085956201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085956201&partnerID=8YFLogxK

U2 - 10.1111/hae.14047

DO - 10.1111/hae.14047

M3 - Letter

C2 - 32497363

AN - SCOPUS:85085956201

SN - 1351-8216

VL - 26

SP - e232-e235

JO - Haemophilia

JF - Haemophilia

IS - 5

ER -